Investigation of the Clinical Performance of Biatain Fiber Ag on Burns

Partial-thickness Burn Clinical Trial

Official title:

Investigation of the Clinical Performance of Biatain Fiber Ag on Burns

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05824026
• Other study ID #: CP357
• Status: Completed
• Phase: N/A
• Start date: October 27, 2023
• Est. completion date: April 26, 2024

Study information

• Verified date: May 2024
• Source: Coloplast A/S
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this study is to test a new gelling fiber wound dressing with silver on patients with a partial thickness burn wound, which is infected or at risk of infection.

Participants will be asked to wear the test dressing in a two weeks period(+/- 2 days) consisting of 3-4 study visits, and will have the dressing changed once pr. week at the research facility. The wound will be cleaned, assessed and photos will be uploaded to a digital software system.

Description:

The clinical investigation is a non-comparative, one-armed, open-labelled, multi-centre study.

The test product, Biatain Fiber Ag is a non-CE-marked gelling fiber wound dressing, containing silver. The product is intended for moist wound healing and exudate management of moderate to high exuding wounds. The product has a classification III, as it contains the active ingredient silver.

The overall purpose of this investigation is to obtain clinical data supporting effectiveness of Biatain Fiber Ag to obtain the CE-mark in EU.

The total study duration for the subject will be approximately two weeks (+/- 2 days), consisting of a two-week test period and 4 study visits (V0/V1, V2 and V3). V3 will also terminate the 2-week study period.

The primary endpoint is percentage of wounds healed within 14 days (≥ 95 % reepithelialisation) The clinical investigation will be conducted in a total of 50 eligible subjects with a partial thickness burn wound that are infected or at risk of infection.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 52
• Est. completion date: April 26, 2024
• Est. primary completion date: April 26, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Has signed informed consent

2. Is between 18 -65 years (both included)

3. Is capable of following study procedure (assessed by investigator).

4. Has a partial thickness burn wound

5. Has a burn wound that is infected or at risk of infection (assessed by investigator)

6. The size of burn (including both study wound and non-study injuries) has a Total Body Surface Area (TBSA) less than 10% (assessed by investigator).

7. The wound should fit under a 20x30 cm dressing (600 cm2) or smaller

8. The shape and location of the wound should be suitable for photo capture (assessed by the investigator).

9. Has a wound that has medium to high level of exudate (assessed by the investigator)

10. Is suitable to use the test product for wound treatment (assessed by the investigator).

Exclusion Criteria:

1. Is pregnant/breastfeeding

2. Is currently receiving or has within the past 60 days received radio- and/or chemotherapy (low doses radio- and/or chemotherapy is allowed for other indications than cancer if assessed by investigator not to influence study wound area)

3. Known history of skin sensitivity to any components of the test dressings

4. >72 hours from time of injury

5. Intake of antibiotics within one week before the start of the enrolment

6. Use of chemical debridement

7. Participation in any other clinical studies that can compromise this study treatment (assessed by the investigator).

Related Conditions & MeSH terms

• Burns
• Partial-thickness Burn

Intervention

Device:
• Gelling fiber wound dressing with silver
intervention involving a wound dressing with silver

Locations

Country	Name	City	State
United Kingdom	Buckinghamshire Healthcare NHS Trust	Aylesbury,	Buckinghamshire
United Kingdom	Queen Alexandra Hospital, Portsmouth Hospital University Trust	Cosham
United Kingdom	Queen Victoria Hospital NHS foundation trust	East Grinstead
United Kingdom	Newcastle University/The Newcastle upon Tyne Hospitals NHS Foundation Trust	Newcastle
United Kingdom	North Bristol Southmead Hospital	Westbury	Bristol

Sponsors (1)

Lead Sponsor	Collaborator
Coloplast A/S

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	percentage of wounds healed within 14 days	to evaluate clinical performance in terms of percentage of wounds achieving healing within 14 days (+/- 2 days). Complete healing is defined as = 95% reepithelisation.	week 2